According to new study published in the Journal of Clinical Investigation, a person’s genotype could be linked with the person’s ability to develop immunity against human immunodeficiency virus (HIV) in response to the vaccine.
In the world are nearly 40 million people living with the virus and developing a vaccine against HIV-1 has been a challenge for which tremendous efforts have been made. In a recent trial of the vaccine against HIV called RV144, it was observed that a combination of two vaccines protect some individuals from infection.
The trial individuals, who were able to generate antibodies linked to a protein’s specific region surrounding the HIV, had lower risk of infection. Researchers at the Cancer Research Center Fred Hutchinson sequenced the genes involved in antibodies production in some of the participants in the trial.
This led to identify single-nucleotide variations in the genes encoding antibody receptors, which are important for immunity. The scientists were able to observe that most of those, who were protected from HIV, presented specific variants in the gene FCGR2C.
In contrast, a different variation of the gen FCGR2C was not associated with protection against HIV. With these results, important information was obtained about the different responses of people who participated in the RV144 vaccine trial.
Via: www.infosalus.com
